![]() This study aimed to analyze the effectiveness of sofosbuvir (SOF) + daclatasvir (DCV) ± ribavirin (RBV) SOF + velpatasvir (VEL) ± RBV SOF + VEL + voxilaprevir (VOX) and glecaprevir (GLE) + pibrentasvir (PIB) in the treatment of HCV GT3-infected patients in real-world studies.Īrticles were identified by searching the PubMed, EMBASE, and Cochrane Library databases from Januto September 10, 2019. Patients with hepatitis C virus (HCV) genotype 3 (GT3) infection are resistant to direct-acting antiviral (DAA) treatments. Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease. Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology. It is the official journal of the Mexican Association of Hepatology ( AMH), the Latin American Association for the Study of the Liver ( ALEH), the Canadian Association for the Study of the Liver ( CASL) and the Czech Society of Hepatology ( CSH). ![]() Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur.
0 Comments
Leave a Reply. |